Sensus Healthcare Brings Groundbreaking SRT-100 Vision System to Israel’s Largest Hospital for Skin Cancer and Keloid Treatment
SRT-100 Vision Coming to Patients at Sheba Medical Center Near Tel Aviv BOCA RATON, Fla., Oct. 17, 2018 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radio Therapy (IGSRT), today announced that the Company has shipped its third […]
South Florida Business Journal Recognizes Sensus Healthcare’s Chief Technology Officer at 2018 Technology Awards
BOCA RATON, Fla., Oct. 16, 2018 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radio Therapy (IGSRT), today announced that the South Florida Business Journal has recognized the Company’s Chief Technology Officer, Kal Fishman, as a finalist at […]
Sensus Healthcare, Inc. Announces Underwriters’ Exercise of Option
BOCA RATON, Fla., Sept. 21, 2018 — Sensus Healthcare, Inc. (Nasdaq: SRTS) announced today that it has issued an additional 330,882 shares of its common stock pursuant to the exercise in full of the underwriters’ option received in connection with Sensus’ recently completed public offering of its common stock. After giving effect to the full […]
Sensus Healthcare, Inc. Announces Closing of Public Offering of Common Stock
BOCA RATON, Fla., Sept. 17, 2018 — Sensus Healthcare, Inc. (Nasdaq: SRTS) announced today that it completed a public offering of 2,205,882 shares of its common stock, par value $0.01 per share, at a public offering price of $6.80 per share. All of the shares were offered by Sensus. The shares are listed on The […]
Sensus Healthcare, Inc. Announces Pricing of Public Offering of Common Stock
BOCA RATON, Fla., Sept. 13, 2018 — Sensus Healthcare, Inc. (Nasdaq: SRTS) announced today that it has priced an underwritten public offering of 2,205,882 shares of its common stock, par value $0.01 per share, at a public offering price of $6.80 per share. Sensus has granted a 30-day option to purchase up to an additional […]
Sensus Healthcare, Inc. Announces Commencement of Public Offering of Common Stock
BOCA RATON, Fla., Sept. 12, 2018 — Sensus Healthcare, Inc. (Nasdaq: SRTS) announced today that it commenced a public offering of its common stock, par value $0.01 per share. B. Riley FBR is serving as the lead underwriter and sole book-running manager for the offering. Sensus intends to use the net proceeds from the offering […]
Sensus Healthcare Presents at National Cancer Care Alliance Leadership Board and Practice Quarterly Meeting
BOCA RATON, Fla., Sept. 7, 2018 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), today announced that Joe Sardano, President and Chief Executive Officer, participated at the National Cancer Care Alliance (NCCA) Leadership Board and Practice Quarterly […]
Sensus Healthcare to Participate in Two Upcoming Investor Conferences
BOCA RATON, Fla., Aug. 27, 2018 — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), today announced that Joe Sardano, President and Chief Executive Officer, will participate at two investor conferences in September 2018, as follows: Annual B. […]
Sensus Healthcare Second Quarter Financial Results Feature Continued Strong Revenue Growth
Ships 21 systems including 12 SRT-100 Vision™ systems Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla., Aug. 2, 2018 — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announces financial results for the three […]
Sensus Healthcare Receives FDA 501(k) Clearance to Market Next-Generation SRT-100+ Superficial Radio Therapy for Treating Non-Melanoma Skin Cancer and Keloids
SRT-100+ Offers Advanced Features for Patients and Doctors, Including Remote Diagnostics and Patient Medical Records Integration, as Well as Core System Enhancements BOCA RATON, Fla., Aug. 2, 2018 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radio Therapy […]
